Abstract
Background:
Translocated in liposarcoma-CCAAT/enhancer binding protein homologous protein (TLS–CHOP) (also known as FUS-DDIT3) chimeric oncoprotein is found in the majority of human myxoid liposarcoma (MLS), but its molecular function remains unclear.
Methods:
We knockdowned TLS–CHOP expression in MLS-derived cell lines by a specific small interfering RNA, and analysed the gene expression profiles with microarray.
Results:
TLS-CHOP knockdown inhibited growth of MLS cells, and induced an anticancer cytokine, melanoma differentiation-associated gene 7 (MDA-7)/interleukin-24 (IL-24) expression. However, double knockdown of TLS–CHOP and MDA-7/IL-24 did not inhibit MLS cell growth.
Conclusion:
Repression of MDA-7/IL-24 expression by TLS–CHOP is required for MLS tumour growth, and TLS–CHOP may become a promising therapeutic target for MLS treatment.
Similar content being viewed by others
Main
More than 90% of human myxoid liposarcoma (MLS) cases are associated with the chromosomal translocation, which creates a chimeric oncogene comprising part of the TLS (translocated in liposarcoma) gene (also known as FUS (fused in Ewing’s sarcoma)) and part of the CHOP (CCAAT/enhancer binding protein (C/EBP) homologous protein) gene (also called DDIT3 (DNA damage-inducible transcript 3) and GADD153 (growth arrest- and DNA damage-inducible gene 153)) (Crozat et al, 1993; Rabbitts et al, 1993; Powers et al, 2010). The resultant fusion gene TLS–CHOP encodes the N-terminal half of TLS fused to complete sequence of CHOP (Powers et al, 2010; Figure 1A). TLS-CHOP protein is considered to function as an abnormal transcription factor (Kuroda et al, 1999; Pérez-Mancera et al, 2008; Andersson et al, 2010). The definitive TLS–CHOP function for MLS development, however, is unclear.
Melanoma differentiation-associated gene 7 (MDA-7)/interleukin-24 (IL-24) protein is expressed in cells of the immune system and normal human melanocytes (Jiang et al, 1995; Wolk et al, 2002). Exogenous expression of MDA-7/IL-24 induces growth arrest and apoptotic cell death in various human malignant cells (Dash et al, 2010; Rahmani et al, 2010).
In this report, we have found a novel pathway of TLS–CHOP with MDA-7/IL-24 repression.
Materials and methods
Cell culture
The MLS-derived cell lines, 1955/91 and 2645/94, were kindly provided from Professor David Ron (University of Cambridge), and were cultured in Dulbecco’s modified Eagle’s medium (Sigma-Aldrich Corporation, St Louis, MO, USA) supplemented with 10% foetal bovine serum. Cell quantification was performed as previously described (Oikawa et al, 2004).
Small interfering RNA transfection
Small interfering RNA (siRNA) transfection (1 μ M final concentration) was performed as previously described (Oikawa et al, 2004). The nucleotide sequences of the chemically synthesised double-stranded siRNAs are as follows: TLS–CHOP siRNA, 5′-GGAAGUGUAUCUUCAUACAdTdT-3′; MDA-7/IL-24 siRNA, 5′-GUGGAUGGGUGCUUAGUAAdTdT-3′; and negative control siRNA, 5′-AUCCGCGCGAUAGUACGUAdTdT-3′.
Detection of TLS–CHOP variants and quantitative real-time PCR analysis
RNA isolation and first-strand cDNA synthesis were performed as previously described (Oikawa et al, 2008a). For detection of TLS–CHOP variants, we performed PCR analysis with TLS–CHOP detection primers 5′-CTTATGGCCAGAGCCAGAAC-3′ and 5′-AAGGCAATGACTCAGCTGCC-3′. The amplification products were sequenced with ABI PRISM 310 Genetic analyser (Applied Biosystems, Foster City, CA, USA). Real-time PCR analysis was performed as previously described (Oikawa et al, 2008b) using TLS–CHOP-specific primers 5′-ATGAACGGCTCAAGCAGGAA-3′ and 5′-TGGTGCAGATTCACCATTCG-3′, and MDA-7/IL-24-specific primers 5′-GTTTTCCATCAGAGACAGTG-3′ and 5′-GTAGAATTTCTGCATCCAGG-3′. The TLS–CHOP and MDA-7/IL-24 mRNA levels were normalised to β-actin signals (Oikawa et al, 2004). We performed real-time PCR analysis in duplicate.
Microarray analysis
Cells were transfected with the TLS–CHOP or negative control siRNAs, and were incubated for 72 h. Biotin-labelled complementary RNA (cRNA) was then generated from 1 μg of total RNA of the cells using CodeLink iExpress Expression Assay Reagent Kit (GE Healthcare UK Ltd, Buckinghamshire, UK), and was hybridised to CodeLink Human Whole Genome Bioarray (GE Healthcare) using iAmplify cRNA Preparation and Hybridisation Reagents Kit (GE Healthcare) according to Expression Bioarray System User Guide ver. 2.0. The array slides were incubated for 21 h at 37 °C with shaking, and were scanned with a DNA microarray scanner G2505A (Agilent Technologies, Inc., Santa Clara, CA, USA). The scanned images were analysed and median normalised using CodeLink Expression Analysis Version 4.1.0.29054 (GE Healthcare). The data have been deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO Series accession number GSE33616.
Western blot analysis
Western blot analysis was performed as previously described (Oikawa et al, 2002). Anti-TLS–CHOP monoclonal antibody (clone 14) was previously generated (Oikawa et al, 2006). Monoclonal anti-α-tubulin antibody clone B-5-1-2 (T-5168; Sigma) was purchased.
Plasmid construction and transfection
To create an MDA-7/IL-24 expression vector, cDNA fragment containing the complete coding region of MDA-7/IL-24 was amplified by PCR using the primers 5′-GCGCGGATCCGAGATGAATTTTCAACAGAG-3′ and 5′-GGCCAAGCTTCCTGGTCTAGACATTCAGAG-3′, and inserted into the mammalian expression vector, pcDNA3.1(−) (Invitrogen, Carlsbad, CA, USA). Plasmid transfection was performed using Lipofectamine 2000 reagent (Invitrogen) and Opti-MEM I Reduced-Serum Medium (Invitrogen).
Results
TLS–CHOP knockdown represses cell growth of MLS-derived cell lines
First, we examined the activity of the three newly designed effective siRNAs that target different positions of TLS–CHOP in a preliminary experiment (Supplementary Figure 1), and selected the most effective siRNA among them (hereafter termed TLS–CHOP siRNA) for use in subsequent experiments. The TLS–CHOP siRNA targets exon 2 of the CHOP gene (Figure 1A). Although types 4 and 11 of TLS–CHOP variants do not have the target region, TLS–CHOP in over 80% of MLS is type 1 or 2. We confirmed that the two MLS-derived cell lines, 1955/91 and 2645/94, carries type 1 and type 2, respectively (Figure 1B). TLS-CHOP knockdown by the siRNA inhibited cell growth and induced cell death in both cell lines (Figure 1C–F). On the other hand, a non-targeting negative control siRNA did not affect cell growth, indicating that the effects of TLS–CHOP siRNA are not by off-target effects.
TLS–CHOP knockdown induces MDA-7/IL-24 expression in MLS cells
Next, we compared mRNA expression profiles of both 1955/91 and 2645/94 cells transfected with TLS–CHOP siRNA or negative control siRNA by microarray analysis (see Materials and Methods). We found that several dozen genes showed at least two-fold differential expression by TLS–CHOP siRNA (Table 1). Among the genes, we focused on the MDA-7/IL-24 gene because it encodes an anticancer cytokine (Dash et al, 2010). TLS-CHOP siRNA induced a significant increase in the expression of MDA-7/IL-24 in both cell lines (Table 1; Figure 2B). Thus, to confirm that MDA-7/IL-24 is important for growth arrest by TLS–CHOP knockdown, we prepared MDA-7/IL-24 siRNA and performed double transfection with both TLS–CHOP and MDA-7/IL-24 siRNAs into 1955/91 cells. MDA-7/IL-24 knockdown cancelled the growth inhibitory effects by TLS–CHOP siRNA alone (Figure 2A and B).
Overexpression of MDA-7/IL-24 represses MLS cell growth
MDA-7/IL-24 displays nearly ubiquitous cancer-specific toxicity (Dash et al, 2010; Rahmani et al, 2010). To confirm that MDA-7/IL-24 is also toxic for MLS, we transfected 1955/91 and 2645/94 cells with an MDA-7/IL-24 expression vector MDA-7/IL-24-pcDNA3.1(−) or a control vector pcDNA3.1(−). As shown in Figure 2C, MDA-7/IL-24-pcDNA(3.1) transfection represses the growth of the cells.
Discussion
We have demonstrated that TLS–CHOP knockdown in MLS cells represses cell growth (Figure 1C–E), suggesting that TLS–CHOP plays an essential role for growth of MLS cells. Furthermore, our results suggest that TLS–CHOP may become a promising molecular target for MLS treatment.
TLS-CHOP knockdown in MLS cells induced increased expression of an anticancer cytokine MDA-7/IL-24 (Table 1; Figure 2B). Thus, we consider that although the cancerous characteristics of MLS cells have potential to induce MDA-7/IL-24 expression, TLS–CHOP represses it and contributes to maintain the tumour growth.
In conclusion, we have revealed a novel pathway involving repression of MDA-7/IL-24 expression for tumourigenesis and/or growth of MLS. We believe that our results will contribute understanding of molecular function of the chimeric oncoprotein and development of a novel molecular therapy for cancers.
Accession codes
Change history
23 January 2013
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Andersson MK, Göransson M, Olofsson A, Andersson C, Aman P (2010) Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop. BMC Cancer 10: 249
Crozat A, Åman P, Mandahl N, Ron D (1993) Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 363: 640–644
Dash R, Bhutia SK, Azab B, Su ZZ, Quinn BA, Kegelmen TP, Das SK, Kim K, Lee SG, Park MA, Yacoub A, Rahmani M, Emdad L, Dmitriev IP, Wang XY, Sarkar D, Grant S, Dent P, Curiel DT, Fisher PB (2010) mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev 21: 381–391
Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB (1995) Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 11: 2477–2486
Kuroda M, Wang X, Sok J, Yin Y, Chung P, Giannotti JW, Jacobs KA, Fitz LJ, Murtha-Riel P, Turner KJ, Ron D (1999) Induction of a secreted protein by the myxoid liposarcoma oncogene. Proc Natl Acad Sci USA 96: 5025–5030
Oikawa K, Akiyoshi A, Tanaka M, Takanashi M, Nishi H, Isaka K, Kiseki H, Idei T, Tsukahara Y, Hashimura N, Mukai K, Kuroda M (2008a) Expression of various types of alternatively spliced WAPL transcripts in human cervical epithelia. Gene 423: 57–62
Oikawa K, Ishida T, Imamura T, Yoshida K, Takanashi M, Hattori H, Ishikawa A, Fujita K, Yamamoto K, Matsubayashi J, Kuroda M, Mukai K (2006) Generation of the novel monoclonal antibody against TLS/EWS-CHOP chimeric oncoproteins that is applicable to one of the most sensitive assays for myxoid and round cell liposarcomas. Am J Surg Pathol 30: 351–356
Oikawa K, Ohbayashi T, Kiyono T, Nishi H, Isaka K, Umezawa A, Kuroda M, Mukai K (2004) Expression of a novel human gene, human wings apart-like (hWAPL), is associated with cervical carcinogenesis and tumor progression. Cancer Res 64: 3545–3549
Oikawa K, Ohbayashi T, Mimura J, Fujii-Kuriyama Y, Teshima S, Rokutan K, Mukai K, Kuroda M (2002) Dioxin stimulates synthesis and secretion of IgE-dependent histamine-releasing factor. Biochem Biophys Res Commun 290: 984–987
Oikawa K, Yoshida K, Takanashi M, Tanabe H, Kiyuna T, Ogura M, Saito A, Umezawa A, Kuroda M (2008b) Dioxin interferes in chromosomal positioning through the aryl hydrocarbon receptor. Biochem Biophys Res Commun 374: 361–364
Pérez-Mancera PA, Bermejo-Rodríguez C, Sánchez-Martín M, Abollo-Jiménez F, Pintado B, Sánchez-García I (2008) FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E. PLoS One 3: e2569
Powers MP, Wang WL, Hernandez VS, Patel KS, Lev DC, Lazar AJ, López-Terrada DH (2010) Detection of myxoid liposarcoma-associated FUS-DDIT3 rearrangement variants including a newly identified breakpoint using an optimized RT-PCR assay. Mod Pathol 23: 1307–1315
Rabbitts TH, Forster A, Larson R, Nathan P (1993) Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 4: 175–180
Rahmani M, Mayo M, Dash R, Sokhi UK, Dmitriev IP, Sarkar D, Dent P, Curiel DT, FIsher PB, Grant S (2010) Melanoma differentiation associated gene-7/interleukin-24 potently induces apoptosis in human myeloid leukemia cells through a process regulated by endoplasmic reticulum stress. Mol Pharmacol 78: 1096–1104
Wolk K, Kunz S, Asadullah K, Sabat R (2002) Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 168: 5397–5402
Acknowledgements
We thank Professor David Ron (University of Cambridge Institute of Metabolic Science, Cambridge, UK) for providing the MLS-derived cell lines. This research was supported in part by a Grant-in-Aid for scientific research on Priority Area (C) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on British Journal of Cancer website
Supplementary information
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Oikawa, K., Tanaka, M., Itoh, S. et al. A novel oncogenic pathway by TLS–CHOP involving repression of MDA-7/IL-24 expression. Br J Cancer 106, 1976–1979 (2012). https://doi.org/10.1038/bjc.2012.199
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bjc.2012.199
Keywords
This article is cited by
-
Role of FUS-CHOP in Myxoid Liposarcoma via miR-486/CDK4 Axis
Biochemical Genetics (2022)
-
Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses
Laboratory Investigation (2018)
-
Molecular detection and targeting of EWSR1 fusion transcripts in soft tissue tumors
Medical Oncology (2013)